Supplementary Table 5. Baseline demographic and clinical characteristics of patients using PPIs and antagonists. Propensity score matched patients H2-Receptor Standardized Characteristic PPI use Antagonist use mean difference† No. of patients 68,856 68,856 Mean age (SD), year 48.3 (15.5) 48.3 (15.4) 0.000 36,515 (53.0) 36,515 (53.0) 0.000 Male (%) Monthly income, NTDs Dependent 14,212 (20.6) 14,208 (20.6) 0.000 <19,100 13,540 (19.7) 13,535 (19.7) 0.000 30,857 (44.8) 30,860 (44.8) 0.000 19,10041,999 42,000 10,247 (14.9) 10,253 (14.9) 0.000 Urbanization* 14,212 (20.6) 14,208 (20.6) 0.000 Level 1 2 13,540 (19.7) 13,535 (19.7) 0.000 Level 3 30,857 (44.8) 30,860 (44.8) 0.000 Level 4 (rural area) 10,247 (14.9) 10,253 (14.9) 0.000 Outpatient visits in the past one year 0-5 visits 11,799 (17.1) 11,795 (17.1) 0.000 6-10 visits 12,574 (18.3) 12,579 (18.3) 0.000 18,618 (27.0) 18,618 (27.0) 0.000 11-20 visits >20 visits 25,865 (37.6) 25,864 (37.6) 0.000 Charlson comorbidity score, mean 4 (3-5) 4 (3-5) 0.003 (IQR)
Supplementary Table 5. Baseline demographic and clinical characteristics of patients using PPIs and antagonists. Propensity score matched patients Characteristic H2-Receptor Antagonist use PPI use Standardized mean difference† No. of patients 68,856 68,856 Mean age (SD), year 48.3 (15.5) 48.3 (15.4) 0.000 Male (%) 36,515 (53.0) 36,515 (53.0) 0.000 Monthly income, NTDs Dependent 14,212 (20.6) 14,208 (20.6) 0.000 <19,100 13,540 (19.7) 13,535 (19.7) 0.000 19,10041,999 30,857 (44.8) 30,860 (44.8) 0.000 42,000 10,247 (14.9) 10,253 (14.9) 0.000 Urbanization* Level 1 14,212 (20.6) 14,208 (20.6) 0.000 2 13,540 (19.7) 13,535 (19.7) 0.000 Level 3 30,857 (44.8) 30,860 (44.8) 0.000 Level 4 (rural area) 10,247 (14.9) 10,253 (14.9) 0.000 Outpatient visits in the past one year 0-5 visits 11,799 (17.1) 11,795 (17.1) 0.000 6-10 visits 12,574 (18.3) 12,579 (18.3) 0.000 11-20 visits 18,618 (27.0) 18,618 (27.0) 0.000 >20 visits 25,865 (37.6) 25,864 (37.6) 0.000 Charlson comorbidity score, mean (IQR) 4 (3-5) 4 (3-5) 0.003
ajg2017101x1.docx